Here's something worth paying attention to: AI-designed molecules are crushing it in early-stage safety trials—we're talking 80-90% success rates. Compare that to the old playbook of 40-65%, and you start seeing why this matters. Drug discovery has always been a numbers game: expensive, slow, high failure rate. But when AI can design molecules that pass safety checks at nearly double the historical rate? That's not just incremental progress. That's the kind of efficiency jump that reshapes entire industries. The implications ripple across biotech, pharmaceutical development, and how we think about human innovation paired with machine learning. Whether it sticks long-term depends on scaling and real-world validation, but the early signals are undeniably strong.